Last reviewed · How we verify

Comparing Patient Satisfaction Throughout the Day With PATADAY (OLOPATADINE HYDROCHLORIDE) 0.2% QD or BEPREVE (BEPOTASTINE BESILATE OPHTHALMIC SOLUTION) 1.5% BID

NCT01450176 NA COMPLETED

The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0.2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1.5%) two times a day (BID).

Details

Lead sponsorMcCabe Vision Center
PhaseNA
StatusCOMPLETED
Enrolment30
Start date2011-09
Completion2011-12

Conditions

Interventions

Primary outcomes

Countries

United States